Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment

Current Opinion in Oncology

Volumn 17, Issue 6, 2005, Pages 539-544

  Smeets, Ann ^a   Christiaens, Marie Rose ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Internal mammary lymph nodes; Isolated tumor cells; Micrometastases; Sentinel lymph node

Indexed keywords

ADJUVANT THERAPY; AXILLA; BREAST TUMOR; CANCER DIAGNOSIS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY;

EID: 27644566186     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000183542.63675.66     Document Type: Review

References (82)

1. Kuehn T, Bembenek A, Decker T. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103:451-461. An excellent review of the current status of the sentinel lymph node biopsy in breast cancer.
2. Goldhirsch A, Wood WC, Gelber RD. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357-3365.
3. Cserni G, Amendoeira I, Apostolikas N. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 2003; 39:1654-1667.
4. Pogacnik A, Klopcic U, Grazio-Frkovic S. The reliability and accuracy of intraoperative imprint cytology of sentinel lymph nodes in breast cancer. Cytopathology 2005; 16:71-76.
5. Litz CE, Beitsch PD, Roberts CA. Intraoperative cytologic diagnosis of breast sentinel lymph nodes in the routine, nonacademic setting: a highly specific test with limited sensitivity. Breast J 2004; 10:383-387.
6. Aihara T, Munakata S, Morino H, Takatsuka Y. Comparison of frozen section and touch imprint cytology for evaluation of sentinel lymph node metastasis in breast cancer. Ann Surg Oncol 2004; 11:747-750. This study demonstrates that the sensitivity of frozen section is almost equivalent to that of touch imprint cytology for evaluation of sentinel lymph node metastasis.
7. Cox C, Centeno B, Dickson D. Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma-A 6-year study. Cancer Cytopathol 2005; 105:13-20.
8. Wada N, Imoto S, Hasebe T. Evaluation of intraoperative frozen section diagnosis of sentinel lymph nodes in breast cancer. Jpn J Clin Oncol 2004; 34: 113-117.
9. Ravichandran D, Kocjan G, Falzon M. Imprint cytology of the sentinel lymph node in the assessment of axillary node status in breast carcinoma. Eur J Surg Oncol 2004; 30:238-242.
10. Holck S, Galatius H, Engel U. False-negative frozen section of sentinel lymph node biopsy for breast cancer. Breast 2004; 13:42-48.
11. Grabau DA, Rank F, Friis E. Intraoperative frozen section examination of axillary sentinel lymph nodes in breast cancer. APMIS 2005; 113:7-12.
12. Fortunato L, Amini M, Farina M. Intraoperative examination of sentinel nodes in breast cancer: Is the glass half full or half empty? Ann Surg Oncol 2004; 11: 1005-1010.
13. Weinberg ES, Dickson D, White L. Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Am J Surg 2004; 188:419-422.
14. Brogi E, Torres-Matundan E, Tan LK, Cody HS. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol 2005; 12:173-180. This study reports comparative results of frozen section and cytology for intraoperative examination of sentinel lymph nodes.
15. Veronesi U, Zurrida S, Mazzarol G, Viale G. Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. World J Surg 2001; 25:806-808.
16. Miltenburg DM, Miller C, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84:138-142
17. Fleming FJ, Kavanagh D, Crotty TB. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol 2004; 57:73-76. Analysis of a prospective database of patients who underwent sentinel lymph node biopsy showing that extranodal extension or macrometastasis within the sentinel lymph node were both independent predictors of non-sentinel lymph node involvement.
18. Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Mod Pathol 2003; 16:25A.
19. Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 2004; 40:1731-1737. Large study revealing that the size of sentinel lymph node metastasis is the most important predictor of involvement of only the sentinel lymph node.
20. Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 2004; 239:859-863. Small study with provocative data.
21. Chua B, Ung O, Taylor R. Treatment implications of a positive sentinel lymph node biopsy for patients with early-stage breast carcinoma. Cancer 2001 ; 92:1769-1774.
22. Farshid G, Pradhan M, Kollias J, Gill PG. A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. Breast 2004; 13:494-501.
23. Viale G, Maiorano E, Pruneri G. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005; 241:319-325. Large study concluding that all patients with positive sentinel lymph nodes should be offered axillary lymph node dissection outside of clinical trials.
24. Veronesi U, Paganelli G, Viale G. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546-553.
25. Langer S, Guenther JM, Haigh PI, DiFronzo LA. Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma. Am Surg 2004; 70:881-885.
26. Rietman JS, Dijkstra PU, Geertzen JHB. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol 2004; 11:1018-1024. Prospective study reporting that there is significantly less upper-limb morbidity after sentinel lymph node biopsy compared with axillary lymph node dissection.
27. Armer JM. Lumphedema following breast cancer treatment, including sentinel lymph node biopsy. Lymphology 2004; 37:73-91.
28. Langer I, Marti WR, Guller U. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases - prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241:152-158.
29. Leidenius M, Krogerus L, Tukiainen E, von Smitten K. Accuracy of axillary staging using sentinel node biopsy or diagnostic axillary lymph node dissection - a case-control study. APMIS 2004; 112:264-270.
30. Naik AM, Fey J, Gemignani M. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection - a follow-up study of 4008 procedures. Ann Surg 2004; 240: 462-468. A very large study with data supporting wider use of sentinel lymph node biopsy. Furthermore, this article gives an overview of studies that have been performed about axillary recurrences after axillary dissection and sentinel lymph node biopsy.
31. Smidt ML, Janssen CMM, Kuster DM. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005; 12:29-33.
32. Jeruss JS, Winchester DJ, Sener SF. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005; 12:34-40.
33. Allweis TM, Badriyyah M, Bar Ad V. Current controversies in sentinel lymph node biopsy for breast cancer. Breast 2003; 12:163-171.
34. Sanjuan A, Vidal-Sicart S, Zanon G. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients. Eur J Nucl Med Mol Imaging 2005; 32:932-936.
35. Kokke MC, Jannink I, Barneveld PC. Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study. Eur J Surg Oncol 2005; 31:221-225.
36. van der Vegt B, Doting MHE, Jager PL. Axillary recurrence after sentinel lymph node biopsy. Eur J Surg Oncol 2004; 30:715-720.
37. Reitsamer R, Peintinger F, Prokop E. 200 Sentinel lymph node biopsies without axillary lymph node dissection -no axillary recurrences after a 3-year follow-up. Br J Cancer 2004; 90:1551-1554.
38. Torrenga H, Fabry H, Van der Sijp JRM. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004; 88:4-7. A small series but one of the longest follow-ups of sentinel lymph node biopsy.
39. Roumen RMH, Kuijt GP, Liem IH, van Seek MWPM. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001; 88:1639-1643.
40. Veronesi U, Galimberti V, Mariani L. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005; 41:231-237. Almost 1000 patients with a median follow-up of 38 months.
41. Viale G, Zurrida S, Maiorano E. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005; 103:492-500. Evaluation of 4351 consecutive patients undergoing sentinel lymph node biopsy. No combination of clinicopathologic features identified patients with a <9.5% risk of sentinel lymph node metastases.
42. Viale G, Sonzogni A, Pruneri G. Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. J Surg Oncol 2004; 85:123-128.
43. Cody HS, Borgen PI, Tan LK. Redefining prognosis in node-negative breast cancer: Can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy? Ann Surg Oncol 2004; 11:227S-230S. Excellent article that emphasizes the implications of the sentinel lymph node biopsy for systemic treatment.
44. Kuehn T, Vogl FD, Helms G. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004; 30:252-259.
45. Catzeddu T, Bertelli G, Del Mastro L, Venturini M. Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective. J Surg Oncol 2004; 85:129-132.
46. Deurloo EE, Tanis PJ, Gilhuijs KGA. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 2003; 39:1068-1073.
47. Sato K, Tamaki K, Tsuda H. Utility of axillary ultrasound examination to select breast cancer patients suited for optimal sentinel node biopsy. Am J Surg 2004; 187:679-683.
48. Zgajnar J, Besic N, Podkrajsek M. Minimal risk of macrometastases in the non-sentinel axillary lymph nodes in breast cancer patients with micrometastatic sentinel lymph nodes and preoperatively ultrasonically uninvolved axillary lymph nodes. Eur J Cancer 2005; 41:244-248.
49. Damera A, Evans AJ, Cornford EJ. Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer 2003; 89:1310-1313.
50. Esen G, Gurses B, Yilmaz MH. Gray scale and power Doppler US in the pre-operative evaluation of axillary metastases in breast cancer patients with no palpable lymph nodes. Eur Radiol 2005; 15:1215-1223. A study reporting that a preoperative ultrasound of the axilla should be included in the preoperative investigation for all patients suitable for SLN biopsy
51. Lovrics PJ, Chen V, Coates G. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11:846-853. This paper shows that the sensitivity of PET compared with axillary lymph node dissection was low whereas PET had high specificity and positive predictive values.
52. Zornoza G, Garcia-Velloso MJ, Sola J.18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004; 30:15-19.
53. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005; 23:1664-1673.
54. Crippa F, Gerali A, Alessi A. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 2004; 31(Suppl 1): S97-102.
55. Giuliano AE, Dale PS, Turner RR. Improved axillary staging of breast-cancer with sentinel lymphadenectomy. Ann Surg 1995; 222:394-401.
56. Veronesi U, Galimberti V, Zurrida S. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001; 37: 454-458.
57. Farshid G, Pradhan M, Kollias J, Gill PG. Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma. Cancer 2000; 89:2527-2537.
58. Gusterson BA. The new TNM classification and micrometastases. Breast 2003; 12:387-390.
59. Viale G, Maiorano E, Mazzarol G. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001 ; 92:1378-1384.
60. Cserni G. A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol 2004; 57:467-471. A geometrical model for sentinel lymph node histopathology in breast cancer.
61. Cserni G, Amendoeira I, Apostolikas N. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 2004; 57:695-701.
62. Cserni G, Bianchi S, Boecker W. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2005; 103:358-367. The results of this study indicate that the definitions available do not permit a reproducible distinction between micrometastases and isolated tumor cells.
63. Colleoni M, Rotmensz N, Peruzzotti G. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005; 23:1379-1389. A large study concluding that even minimal involvement of axillary lymph nodes significantly correlates with worse prognosis.
64. Sakorafas GH, Geraghty J, Pavlakis G. The clinical significance of axillary lymph node micrometastases in breast cancer. Eur J Surg Oncol 2004; 30: 807-816.
65. Louis-Sylvestre C, Clough K, Asselain B. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004; 22: 97-101.
66. Schwartz GF. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J 2004; 10: 85-88.
67. Cserni G, Gregori D, Merletti F. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91:1245-1252. Meta-analysis showing that the risk of non-sentinel lymph node metastases in patients with a low-volume metastasis in the sentinel lymph node is around 10-15%.
68. Teng MS, Dupont E, McCann C. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg 2000; 66:574-578.
69. Schrenk P, Konstantiniuk P, Wolfl S. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 2005; 92:707-713.
70. Leidenius MHK, Vironen JH, Riihela MS. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur J Surg Oncol 2005; 31:13-18.
71. Giard S, Baranzelli MC, Robert D. Surgical implications of sentinel node with micrometastatic disease in invasive breast cancer. Eur J Surg Oncol 2004; 30:924-929.
72. Turner RR, Chu KU, Qi K. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89:574-581.
73. Estourgie SH, Tanis PJ, Nieweg OE. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003; 10:935-941.
74. Veronesi U, Cascinelli N, Bufalino R. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 1983; 198:681-684.
75. Lacour J, Le M, Caceres E. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983; 51:1941-1943.
76. Veronesi U, Marubini E, Mariani L. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 1999; 35:1320-1325.
77. Veronesi U, Cascinelli N, Greco M. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985; 202: 702-707.
78. Colleoni M, Zahrieh D, Gelber RD. Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Study Group experience. J Clin Oncol 2005; 23:1390-1400. A study demonstrating that medial site of breast cancers is an important prognostic feature.
79. Tanis PJ, Nieweg OE, Olmos RAV, Kroon BBR. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 2001; 192:399-409.
80. Galimberti V, Veronesi P, Arnone P. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol 2002; 9:924-928.
81. Nieweg OE, Bartelink H. Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. Eur J Cancer 2004; 40: 179-181.
82. Farrus B, Vidal-Sicart S, Velasco M. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan, Int J Radiat Oncol Biol Phys 2004; 60:715-721.